Keyphrases
Indonesia
100%
Smooth muscle
84%
Randomized Controlled Trial
64%
Granulocyte Colony-stimulating Factor (G-CSF)
56%
COVID-19
56%
Pediatric
56%
Phosphodiesterase
56%
Decompensated Cirrhosis
49%
Isoenzymes
45%
Jakarta
43%
Erectile Dysfunction
39%
Liver Transplantation
39%
Hepatocyte Apoptosis
37%
Cyclic nucleotide Phosphodiesterase
37%
Obstructive Jaundice
37%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
37%
Neoadjuvant Chemotherapy
37%
Clinical Response
37%
Phosphodiesterase Inhibitors
35%
Cyclic GMP
34%
Vasoactive Intestinal Polypeptide
31%
Pediatric End-stage Liver Disease
31%
Ureter
31%
Melatonin
30%
Decompression
30%
Relaxation Effect
30%
C-type Natriuretic Peptide
29%
Bradykinin
29%
Locally Advanced
26%
Endothelin-1 (ET-1)
26%
Bile Duct
25%
Cyclic Adenosine Monophosphate (cAMP)
25%
Sildenafil
24%
Intervention Group
24%
Indonesian
24%
Risk Factors
23%
Nutritional Status
23%
Aging Male Symptoms
22%
Y Chromosome Microdeletion
21%
Expression Response
21%
Azoospermic Men
21%
Pretransplant
21%
Non-communicable Diseases
21%
Human Ureter
21%
Hypoxia-inducible factor-1α (HIF-1α)
21%
Vaginal Tissue
20%
Phosphodiesterase-4 (PDE4)
20%
Liver Function
19%
Objective Structured Clinical Examination
18%
Oligozoospermic
18%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphodiesterase
56%
Isoenzyme
46%
Randomized Controlled Trial
44%
Erectile Dysfunction
39%
Phosphodiesterase Inhibitor
37%
Granulocyte Colony Stimulating Factor
37%
Melatonin
37%
Natriuretic Peptide Type C
37%
Bradykinin
37%
Mouth Squamous Cell Carcinoma
37%
Cyclic Nucleotide Phosphodiesterase
37%
Chemotherapy
37%
Obstructive Jaundice
37%
Vasoactive Intestinal Polypeptide
35%
Combination Therapy
31%
Decompensated Liver Cirrhosis
31%
Cyclic AMP
26%
Cyclic GMP
25%
Symptom
25%
Phosphodiesterase V Inhibitor
22%
End Stage Liver Disease
19%
Endothelin 1
19%
Hypoxia Inducible Factor
18%
Alpha Adrenergic Receptor Blocking Agent
18%
Pelvis Pain Syndrome
18%
Proteinase
18%
Serotonin Reuptake Inhibitor
18%
Selective Serotonin Reuptake Inhibitor
18%
Urodilatin
18%
Monotherapy
18%
Chronic Prostatitis
18%
microRNA 210
18%
Antibiotics
18%
Randomized Clinical Trial
18%
Hydrocortisone
18%
Vardenafil
18%
Bile Acid
18%
Sildenafil
18%
Male Infertility
18%
Premature Ejaculation
18%
Tolerability
18%
Lower Urinary Tract Symptom
18%
Malignant Neoplasm
18%
Kidney Stone
18%
Tablet
17%
Hypoxia Inducible Factor 1
16%
Big Endothelin 1
16%
Neoplasm
16%
Cyclic Nucleotide
15%
Phosphodiesterase IV Inhibitor
15%
Medicine and Dentistry
Granulocyte Colony Stimulating Factor
56%
Pediatrics
56%
Decompensated Liver Cirrhosis
49%
COVID-19
44%
Randomized Controlled Trial
44%
Liver Transplantation
39%
Smooth Muscle
37%
Cyclic Nucleotide Phosphodiesterase
37%
In Vitro
37%
Phosphodiesterase
37%
End Stage Liver Disease
31%
Combination Therapy
30%
Isoenzyme
28%
Symptom
27%
Azoospermia
24%
Nutritional Status
23%
Quality of Life
22%
Urology
21%
Diabetes Mellitus
21%
Erectile Dysfunction
21%
Side Effect
19%
Phosphodiesterase Inhibitor
19%
Liver Function
19%
Autosuggestion
18%
Endocrine Immunology
18%
Antibiotics
18%
Transurethral Resection
18%
Clinical Examination
18%
Nitric Oxide Donor
18%
Urodilatin
18%
microRNA 210
18%
Melatonin
18%
Chronic Pelvic Pain Syndrome
18%
Chronic Prostatitis
18%
Alpha Adrenergic Receptor Blocking Agent
18%
Systematic Review
18%
Monotherapy
18%
Breast Cancer-Related Lymphedema
18%
Andropause
18%
Health System
18%
Male Infertility
18%
Axillary Lymph Node
18%
Geriatrics
18%
Ureter
18%
Obstructive Jaundice
18%
Bile Duct
18%
Bile
18%
Innate Immunity
18%
Neoadjuvant Chemotherapy
18%
Locally Advanced Breast Cancer
18%